Hong Yin | OMICS International

Atherosclerosis: Open Access
Open Access

Like us on:

Our Group organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Hong Yin

Amgen Biopharmaceutical Research & Development (Shanghai) Co., Ltd, Shanghai, China 4F, Building 6, 99 Haike Road, Shanghai, 201210, PR China


Hong Yin is the member of Amgen Biopharmaceutical Research & Development (Shanghai) Co., Ltd, Shanghai, China. 
He is board certified in Internal Medicine, Cardiovascular Disease, Interventional Cardiology and Endovascular Medicine. Hong Yin is a member of multiple professional societies.

Prevalence and Outcomes of Familial Hypercholesterolemia Patients in a Chinese Myocardial Infarction Cohort

Background and aims: Familial Hypercholesterolemia (FH) is an inherited metabolic disorder with increased LDL-C levels and coronary heart disease (CHD) risk. The prevalence of heterozygous FH is approximately 1:200 to 1:500 worldwide and higher in CHD populations. We aim to estimate the prevalence of FH and the incidence of recurrent cardiovascular... Read More»

Yan Gao, Hong Yin, Ying He, Jihua Wu, Siming Wang, Wenjin Li, Xi Li, Ouhong Wang, Mingqiang Zhang and Lixin Jiang

Research Article: Atheroscler Open Access 2017, 2:114

Abstract Peer-reviewed Full Article Peer-reviewed Article PDF Mobile Full Article

Global Speakers in the subject

Global Experts in the subject